Pyxis Oncology reports positive updated Phase 1 MICVO monotherapy data
Pyxis Oncology says updated Phase 1 monotherapy study data for micvotabart pelidotin (MICVO) is positive in 2L+ recurrent/metastatic head and neck squamous cell carcinoma.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.